A New Age
"It is no longer acceptable to dismiss mesothelioma as untreatable, for untreatable implies an "acceptance" of failure. We must dispel this attitude of nihilism by education and the establishment of treatment networks. If we can be as aggressive with our investigations of novel therapies for mesothelioma as we are with breast and prostate cancer, we may avoid the perpetuation of this tragedy into the new millennium." Dr. Harvey Pass is the Head of Thoracic Oncology at the Karmanos Cancer Institute in Detroit ( one of the 37 NCI designated Comprehensive Cancer Centers) and has studied pleural mesothelioma since 1988 when he was the Head of Thoracic Oncology and Senior Investigator of the Surgery Branch of the National Cancer Institute in Bethesda. Dr. Pass combines cytoreductive surgery, either EPP or pleurectomy, with innovative or standard adjuvant therapies including novel antiangiogenesis inhibitors postoperatively or chemotherapy combinations. His Thoracic Oncology laboratory is pursuing the study of proteins (proteomics) and gene expression profiles in mesothelioma to develop new early detection strategies, as well as designing alternate innovative treatments which use novel proteins as targets for mesothelioma |
